BRPI1009606A2 - método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição - Google Patents

método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição

Info

Publication number
BRPI1009606A2
BRPI1009606A2 BRPI1009606A BRPI1009606A BRPI1009606A2 BR PI1009606 A2 BRPI1009606 A2 BR PI1009606A2 BR PI1009606 A BRPI1009606 A BR PI1009606A BR PI1009606 A BRPI1009606 A BR PI1009606A BR PI1009606 A2 BRPI1009606 A2 BR PI1009606A2
Authority
BR
Brazil
Prior art keywords
multiple sclerosis
treating
microparticle
symptoms
linked
Prior art date
Application number
BRPI1009606A
Other languages
English (en)
Inventor
Frank B Gelder
Gillian Alison Webster
Original Assignee
Innate Immunotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Immunotherapeutics Ltd filed Critical Innate Immunotherapeutics Ltd
Publication of BRPI1009606A2 publication Critical patent/BRPI1009606A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Photographic Developing Apparatuses (AREA)
BRPI1009606A 2009-06-16 2010-01-16 método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição BRPI1009606A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ577731A NZ577731A (en) 2009-06-16 2009-06-16 Compositions and methods for treatment of multiple sclerosis
PCT/NZ2010/000112 WO2010147484A1 (en) 2009-06-16 2010-06-16 Compositions and methods for treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
BRPI1009606A2 true BRPI1009606A2 (pt) 2016-10-11

Family

ID=42646236

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009606A BRPI1009606A2 (pt) 2009-06-16 2010-01-16 método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição

Country Status (21)

Country Link
US (1) US8389479B2 (pt)
EP (1) EP2442832B1 (pt)
JP (1) JP5646617B2 (pt)
CN (1) CN102458476B (pt)
AU (1) AU2010260585B2 (pt)
BR (1) BRPI1009606A2 (pt)
CA (1) CA2688766C (pt)
CY (1) CY1115714T1 (pt)
DK (1) DK2442832T3 (pt)
ES (1) ES2521565T3 (pt)
HK (1) HK1167101A1 (pt)
HR (1) HRP20141035T1 (pt)
IL (1) IL216993A (pt)
IN (1) IN2012DN00167A (pt)
MX (1) MX2011013661A (pt)
NZ (1) NZ577731A (pt)
PL (1) PL2442832T3 (pt)
PT (1) PT2442832E (pt)
SI (1) SI2442832T1 (pt)
SM (1) SMT201400165B (pt)
WO (1) WO2010147484A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5569944B2 (ja) * 2008-04-01 2014-08-13 イネイト・イムノセラピューティクス・リミテッド 抗感染薬およびその使用
LT3326645T (lt) 2010-10-25 2020-08-10 Biogen Ma Inc. Alfa-4 integrino aktyvumo skirtumų, koreliuojant su skirtumais svcam ir (arba) smadcam lygiuose, nustatymo būdai
UY35790A (es) * 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2017059486A1 (en) * 2015-10-06 2017-04-13 Innate Immunotherapeutics Limited Compositions and methods for the treatment of epilepsy
KR20170041116A (ko) * 2015-10-06 2017-04-14 이네이트 이뮤노테라퓨틱스 리미티드 신경계의 보호 및/또는 복구용 조성물 및 방법
WO2017070731A1 (en) * 2015-10-28 2017-05-04 Innate Immunotherapeutics Limited Compositions and methods for the treatment of alzheimer's disease
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
WO2019218079A1 (en) * 2018-05-18 2019-11-21 Universite Laval Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease
US20210169904A1 (en) * 2018-07-03 2021-06-10 University Of Florida Research Foundation, Incorporated Microparticle systems and their use for the treatment of multiple sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU732809B2 (en) * 1996-10-10 2001-05-03 Innate Immunotherapeutics Limited Compositions and methods for treating viral infections
AU2005259726A1 (en) * 2004-07-01 2006-01-12 Kobenhavns Universitet Method for multiple sclerosis treatment and prophylaxis by treatment of Leptospira infection
WO2008070564A1 (en) 2006-12-01 2008-06-12 The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services Uses of muramyl dipeptide (mdp) for treating inflammation
JP2008251608A (ja) 2007-03-29 2008-10-16 Casio Comput Co Ltd 半導体装置およびその製造方法
WO2008150182A1 (en) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treatment of anthrax
WO2008150181A1 (en) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treating anthrax exposure associated conditions

Also Published As

Publication number Publication date
DK2442832T3 (da) 2014-11-10
CY1115714T1 (el) 2017-01-25
MX2011013661A (es) 2012-05-22
AU2010260585B2 (en) 2013-02-21
US20100317589A1 (en) 2010-12-16
CN102458476A (zh) 2012-05-16
AU2010260585A8 (en) 2012-06-14
SI2442832T1 (sl) 2014-12-31
JP5646617B2 (ja) 2014-12-24
PL2442832T3 (pl) 2015-01-30
HK1167101A1 (en) 2013-02-01
WO2010147484A8 (en) 2012-07-19
EP2442832A1 (en) 2012-04-25
WO2010147484A1 (en) 2010-12-23
CN102458476B (zh) 2014-08-20
IL216993A0 (en) 2012-02-29
JP2012530132A (ja) 2012-11-29
EP2442832A4 (en) 2013-07-03
CA2688766C (en) 2015-06-30
PT2442832E (pt) 2014-11-11
AU2010260585A1 (en) 2012-01-19
NZ577731A (en) 2010-08-27
ES2521565T3 (es) 2014-11-12
EP2442832B1 (en) 2014-08-06
IN2012DN00167A (pt) 2015-04-17
SMT201400165B (it) 2015-01-15
HRP20141035T1 (hr) 2014-12-19
US8389479B2 (en) 2013-03-05
CA2688766A1 (en) 2010-12-16
IL216993A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
BRPI1009606A2 (pt) método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição
BRPI1014824A2 (pt) composição farmacêutica em forma de dose unitária e método de tratamento, prevenção ou redução da ocorrência de uma condição em um indivíduo
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0911612A2 (pt) composições e métodos para o tratamento da esclerose múltipla.
BRPI0815283A2 (pt) Equipamento para o tratamento da biomassa, método para o tratamento da biomassa, biomassa tratada e hidrolisado
BRPI1008974A2 (pt) composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0815387A2 (pt) composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
BRPI0920326A2 (pt) composição e método para tratamento da síndrome do olho ressecado
IL218257A (en) A solid pharmaceutical preparation containing sglt-2 inhibitor and metformin and this drug for the treatment of metabolic disorders
BRPI0810806A2 (pt) Método para tratar uma lesão cutânea em um indivíduo
BRPI1004899A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac
BRPI0921317A2 (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BRPI0922301A2 (pt) combinações de inibidor de hsp90
BR112013026341A2 (pt) composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
BRPI0716210A2 (pt) Métodos, composições e aparelhos para tratar feridas com pressões diferentes da atmosférica
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
EP2214707A4 (en) COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION
HK1203044A1 (en) Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders cns
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI0820967A2 (pt) Uso de uma composição, composição farmacêutica e método para tratamento, melhora ou profilaxia dos sintomas de uma doença inflamatória
BRPI1000030A2 (pt) métodos para tratar esclerose múltipla em um paciente, para aumentar a capacidade de caminhar, para tratar os sintomas da esclerose múltipla, e, composição.
BRPI0919759A2 (pt) polipeptídeos para tratamento e prevenção de adesões
FI20095893L (fi) Kovettuva koostumus, kovettunut tuote sekä laminaatti
BRPI0916102A2 (pt) "método para a prevenção da hérnia paraestomal, método para preparar uma hérnia paraestomal e dispositivo para preparar ou reduzir a incidência da hérnia paraestomal"

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]